A Case of Macrophage Activation Syndrome During the Treatment of Adult-onset Still's Disease With Tocilizumab
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이주호 | - |
dc.contributor.author | 하유정 | - |
dc.contributor.author | 강은하 | - |
dc.contributor.author | 장성혜 | - |
dc.contributor.author | 이윤종 | - |
dc.date.accessioned | 2022-05-10T00:47:38Z | - |
dc.date.available | 2022-05-10T00:47:38Z | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 2093-940X | - |
dc.identifier.issn | 2233-4718 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/20731 | - |
dc.description.abstract | Macrophage activation syndrome (MAS) is a fatal complication of adult-onset Still’s disease (AOSD). Although anti-cytokine agents have been recommended for refractory AOSD or complicated with MAS, MAS cases have been rarely reported during anticytokine treatment. Herein, we describe the first AOSD case complicated with MAS during the treatment with tocilizumab in Korea. Two years after tocilizumab maintenance therapy, high fever and hypertransaminasemia recurred. MAS was diagnosed based on hyperferritinemia, elevated soluble IL-2 receptor levels, and the presence of hemophagocytic histiocytes in the bone marrow. However, she had normal white blood cell counts and acute phase reactant levels. High-dose glucocorticoid and anakinra therapies were not effective, but her disease improved with etoposide. This case shows that tocilizumab may not prevent MAS development and can modify clinical features making it challenging to diagnose. Cytotoxic therapy such as etoposide may be required in MAS cases that develop during anti-cytokine therapy. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한류마티스학회 | - |
dc.title | A Case of Macrophage Activation Syndrome During the Treatment of Adult-onset Still's Disease With Tocilizumab | - |
dc.title.alternative | A Case of Macrophage Activation Syndrome During the Treatment of Adult-onset Still's Disease With Tocilizumab | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4078/jrd.2022.29.2.123 | - |
dc.identifier.scopusid | 2-s2.0-85128822751 | - |
dc.identifier.wosid | 000782477500010 | - |
dc.identifier.bibliographicCitation | 대한류마티스학회지, v.29, no.2, pp 123 - 128 | - |
dc.citation.title | 대한류마티스학회지 | - |
dc.citation.volume | 29 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 123 | - |
dc.citation.endPage | 128 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002827283 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordAuthor | Still&rsquo | - |
dc.subject.keywordAuthor | s disease | - |
dc.subject.keywordAuthor | adult-onset | - |
dc.subject.keywordAuthor | Macrophage activation syndrome | - |
dc.subject.keywordAuthor | Lymphohistiocytosis | - |
dc.subject.keywordAuthor | hemophagocytic | - |
dc.subject.keywordAuthor | Tocilizumab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.